Recent advances in the management of hyponatremia in cancer patients

Abstract

Hyponatremia is the most frequently encountered electrolyte disorder in cancer patients and is usually multifactorial in its origin. In this review, we discuss the predisposing factors, pathophysiology, clinical symptomatology, and currently available diagnostic and therapeutic options for the management of hyponatremia. In addition to paraneoplastic syndromes, concurrent chemotherapy and comorbidities predispose oncology patients to the risk of hyponatremia. Initial symptoms and signs can be subtle and the prompt evaluation and initiation of treatment is of paramount importance to prevent neurocognitive and other complications. The syndrome of inappropriate antidiuresis (SIAD) is the most common cause of hyponatremia, and the use of serum and urine parameters that distinguish SIAD from other etiologies is discussed. Individualized treatment is preferred depending on the underlying cause and severity of hyponatremia. The treatment of hyponatremia is reviewed and the importance of avoiding rapid overcorrection of the sodium level to reduce the risk of osmotic demyelination syndrome is emphasized. Vasopressin receptor antagonists (vaptans) offer a direct approach to the management of euvolemic and hypervolemic hyponatremia, but the indications for their use and long-term safety need to be clarified. The treatment of hyponatremia is likely to reduce complications and improve survival in cancer patients.

Keywords

Hyponatremia / electrolyte abnormalities / dysnatremias / cancer

References

[1] Onitilo AA,Doi SA.Tumor-related hyponatremia..Clin Med Res2007;5:228-37 PMCID:PMC2275758

[2] Stelfox HT,Khandwala F,Shahpori R.The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units..Crit Care2008;12:R162 PMCID:PMC2646327

[3] Funk GC,Druml W,Schwarz C.Incidence and prognosis of dysnatremias present on ICU admission..Intensive Care Med2010;36:304-11

[4] Berardi R,Castagnani M,Marcucci F.Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients..Support Care Cancer2015;23:3095-101

[5] Doshi SM,Lei X,Salahudeen AK.Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes..Am J Kidney Dis2012;59:222-8

[6] Gralla RJ,Blais JD,Zhou W.Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials..Cancer Med2017;6:723-9 PMCID:PMC5387121

[7] Castillo JJ,Justice E.Diagnosis and management of hyponatremia in cancer patients..Oncologist2012;17:756-65 PMCID:PMC3380874

[8] Platania M,Vitali M.Hyponatremia in cancer patients..Tumori2015;101:246-8

[9] Balachandran K,Gunapala R,Popat S.Resolution of severe hyponatraemia is associated with improved survival in patients with cancer..BMC Cancer2015;15:163 PMCID:PMC4381411

[10] Spasovski G,Allolio B,Ball S.Clinical practice guideline on diagnosis and treatment of hyponatraemia..Nephrol Dial Transplant.2014;29 Suppl 2:i1-39

[11] Berardi R,Newsom-Davis T,Rinaldi S.Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy..Oncotarget2017;8:23871-9 PMCID:PMC5410351

[12] Hansen O,Hansen KH.The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period..Lung Cancer2010;68:111-4

[13] Lehrich RW,Patel MB.Role of vaptans in the management of hyponatremia..Am J Kidney Dis2013;62:364-76

[14] Maesaka JK,Mattana J,Bade N.Differentiating SIADH from cerebral/renal salt wasting: failure of the volume spproach and need for a new spproach to hyponatremia..J Clin Med2014;3:1373-85 PMCID:PMC4470189

[15] Robertson GL.Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis..Am J Med2006;119(7 Suppl 1):S36-42

[16] Moritz ML.Syndrome of inappropriate antidiuresis..Pediatr Clin North Am2019;66:209-26

[17] Kamoi K,Kobayashi O,Sato F.Atrial natriuretic peptide in patients with the syndrome of inappropriate antidiuretic hormone secretion and with diabetes insipidus..J Clin Endocrinol Metab1990;70:1385-90

[18] Hillier TA,Barrett EJ.Hyponatremia: evaluating the correction factor for hyperglycemia..Am J Med1999;106:399-403

[19] Verbalis JG,Greenberg A,Schrier RW.Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations..Am J Med2013;126 (10 Suppl 1):S1-42

[20] Miller M.Syndromes of excess antidiuretic hormone release..Crit Care Clin2001;17:11-23

[21] Cerdà-Esteve M,Chillaron JJ,Cucurella G.Cerebral salt wasting syndrome: review..Eur J Intern Med2008;19:249-54

[22] Holland-Bill L,Farkas DK,Jorgensen JOL.Diagnosis of hyponatremia and increased risk of a subsequent cancer diagnosis: results from a nationwide population-based cohort study..Acta Oncol2018;57:522-7

[23] Henry DA.In the clinic: hyponatremia..Ann Intern Med2015;163:1-19

[24] Harrigan MR.Cerebral salt wasting syndrome..Crit Care Clin2001;17:125-38

[25] Yee AH,Wijdicks EF.Cerebral salt wasting: pathophysiology, diagnosis, and treatment..Neurosurg Clin N Am2010;21:339-52

[26] Betjes MG.Hyponatremia in acute brain disease: the cerebral salt wasting syndrome..Eur J Intern Med2002;13:9-14

[27] Palmer BF.Hyponatremia in the intensive care unit..Semin Nephrol2009;29:257-70

[28] Rivkees SA.Differentiating appropriate antidiuretic hormone secretion, inappropriate antidiuretic hormone secretion and cerebral salt wasting: the common, uncommon, and misnamed..Curr Opin Pediatr2008;20:448-52

[29] Gurnurkar S,Warner L.Successful use of fludrocortisone in a child with refractory cerebral salt wasting syndrome: a case report and review of literature..Cureus2018;10:e3505 PMCID:PMC6318137

[30] Refardt J,Christ-Crain M.Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis..Clin Endocrinol (Oxf)2019;91:22-32

[31] Hoorn EJ.Diagnosis and treatment of hyponatremia: compilation of the guidelines..J Am Soc Nephrol2017;28:1340-9 PMCID:PMC5407738

[32] Janicic N.Evaluation and management of hypo-osmolality in hospitalized patients..Endocrinol Metab Clin North Am2003;32:459-81

[33] Adrogue HJ.Hyponatremia..N Engl J Med2000;342:1581-9

[34] Cherrill DA,Birge JR.Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion..Ann Intern Med1975;83:654-6

[35] Mori T,Kawamata T.Improved efficiency of hypervolemic therapy with inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid hemorrhage..J Neurosurg1999;91:947-52

[36] Lampl C.Central pontine myelinolysis..Eur Neurol2002;47:3-10

[37] Dokmak A.Hyponatremia and in-hospital falls and fractures in older adults..J Am Geriatr Soc2019;67:1752-3

[38] Sterns RH.The management of symptomatic hyponatremia..Semin Nephrol1990;10:503-14

[39] Adrogue HJ.Diagnosis and treatment of hyponatremia..Am J Kidney Dis2014;64:681-4

[40] Sood L,Hix JK,Chen L.Hypertonic saline and desmopressin: a simple strategy for safe correction of severe hyponatremia..Am J Kidney Dis2013;61:571-8

[41] Gross PA,Decaux G.Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet..Kidney Int2011;80:594-600

[42] Verbalis JG,Smith N,Andoh M.Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study..Clin Endocrinol (Oxf)2008;69:159-68

[43] Schrier RW,Gheorghiade M,Verbalis JG.Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia..N Engl J Med2006;355:2099-112

[44] Chiong JR,Lin J,Dasta JF.Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial..J Med Econ2012;15:276-84

[45] Peri A.Clinical review: the use of vaptans in clinical endocrinology..J Clin Endocrinol Metab2013;98:1321-32

[46] Khan MI,Waguespack SG.Electrolyte disturbances in critically Ill cancer patients: an endocrine perspective..J Intensive Care Med2018;33:147-58